| Name | Title | Contact Details |
|---|
We outfit youth sports teams with customized gear – on time for game time!
Wren Kitchens have been an industry leader in kitchen manufacturing for both the UK and US markets for over 35 years, and has now become the UKs fastest growing designer, manufacturer and retailer of fully built kitchen units. We currently have 111 showrooms, and plan to continue our expansion with many more. Complementing our state-of-the art showrooms is a truly cutting-edge online service, honed over the last five years through the development of Ebuyer.com, which generates in excess of £200 million of sales each year. We support this with a highly advanced logistics and distribution network, ensuring that the quality we demand from our products is continued throughout the delivery process. We truly believe this is what makes Wren Kitchens stand out as the premier choice for all your kitchen needs. The Wren Difference Great care is taken to make sure that the standard of our products is consistently high, starting with the materials. We use only the best-quality materials, FSC sourced in the UK, with carcase ends, shelves and rails constructed from melamine-faced chipboard and back panels from medium density fibreboard. These are glued together with our unique Bond-X system, ensuring the finished product retains its high quality for years to come.
HPI redefines what is possible with self-funded health plans. As a third-party administrator, we partner with health plan brokers and employers to provide innovative self-funding strategies and customized plans tailored to each clients needs and population. Our solutions give employers greater cost transparency and control, while elevating the member experience.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.